ClinicalTrials.gg
RecruitingNCT06925152COMFORTUpdated Oct 21, 2026

COMFORT Trial: Complex Obstetric Management With Focused Regional Transversus Abdominis Plane Block

A Phase 4 interventional study of Bupivicaine intervention arm and Placebo arm in Complex Obstetric Surgery, Perioperative Pain Management and Cesarean Delivery, sponsored by University of Tennessee. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Primary conditionPain, PostoperativeRegistry: PainReclassifiedWhy we changed it
Registry
Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pain, Postoperative
Why
  1. The study's listed conditions name Pain, Postoperative, a narrower term within Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Tennessee · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Oct 21, 2026Eligibility revisedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,181 studies in Pain, Postoperative with a site in United States — 204 open to participants now, 237 under way, 25 of them phase 3. Pain, Postoperative · United States.

Planned enrollment
306th of 1,099
120 · median 76
Started
2025
with 48 others
Phase 4
359 of 1,181
72 open now
Primary completion
2028-05
later than 203 of 236 live
Registered
1,082nd of 1,181
by date

Among the 1,181 studies in Pain, Postoperative with a site in United States, this one is the 306th largest by planned enrollment of the 1,099 interventional ones that give a count, is one of 49 that started in 2025, is one of 359 in phase 4, reaches primary completion later than 203 of the 236 other live ones, and was the 1,082nd registered.

Pain, Postoperative

5,675 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

204 of the 1,181 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:

199 more — sign in →

All 204 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,181 studies in Pain, Postoperative with a site in United States, or all of them as a file.
02

Study summary

To assess the effect of intraoperative transversus abdominis plane (TAP) blocks on the amount of opioid pain medications expressed as morphine milliequivalents (MME) used postoperatively in patients who have undergone cesarean delivery (CD) in the setting of complex obstetric surgery (COS).

Read the detailed description

The Transversus Abdominis Plane (TAP) block is a regional anesthesia technique that targets the nerves innervating the abdominal wall, providing effective postoperative analgesia for patients undergoing various abdominal surgeries, including cesarean deliveries. The standard clinical practice for TAP blocks typically involves local anesthetics like bupivacaine, which, when administered in the appropriate plane, has been shown to reduce opioid consumption and improve pain management in the postoperative period.

Transversus abdominal plane (TAP) blocks, when administered intraoperatively, have demonstrated significant benefits in managing postoperative pain, especially in abdominal surgeries. Placing the TAP block during surgery provides early and prolonged analgesia, potentially reducing the need for postoperative opioids and improving recovery outcomes. A study completed in 2007 was one of the first to highlight the effectiveness of intraoperative TAP block placement in patients undergoing lower abdominal surgeries, showing a significant reduction in opioid consumption and better pain control. In the context of cesarean section, an intraoperative TAP block was shown to provide effective analgesia with a reduction in postoperative narcotic use. Similarly, a randomized trial in 2017 demonstrated that intraoperative TAP blocks significantly improved pain scores and reduced opioid consumption in patients undergoing colorectal surgeries. Furthermore, a study completed in 2014 found that performing TAP blocks intraoperatively for laparoscopic cholecystectomy patients resulted in lower visual analog scale (VAS) pain scores in the recovery room and reduced the incidence of postoperative nausea and vomiting. These findings underscore the advantages of intraoperative TAP block placement in enhancing postoperative analgesia across a variety of abdominal procedures.

Despite the widespread use of TAP blocks, there remains a gap in the literature regarding the effectiveness of bupivacaine TAP block use placed intraoperatively during more complex obstetric surgeries. Most existing studies focus on the use of TAP blocks for pain management after routine Pfannenstiel cesarean deliveries, with limited attention given to their role in cases involving higher-risk or more complicated obstetric situations, such as cesareans with significant intra-abdominal adhesions or other complications.

Although bupivacaine is commonly used in TAP blocks, its specific efficacy, optimal dosing, and potential benefits when placed intraoperatively in complex obstetric cases remain underexplored. The limited data in this area presents a critical gap in our understanding of how best to optimize pain management and improve surgical outcomes for women undergoing cesarean delivery, particularly in high-risk obstetric cases.

This blinded randomized controlled trial (RCT) seeks to address this gap by evaluating the effectiveness of intraoperative TAP blocks with bupivacaine during complex cesarean sections, focusing on the impact on postoperative analgesia and pain scores. By clarifying the role of bupivacaine in TAP blocks during complex obstetric surgery, this study aims to contribute valuable insights to the field of obstetric anesthesia and improve the perioperative experience for patients undergoing cesarean delivery.

Primary Objective: To assess the effect of intraoperative transversus abdominis plane (TAP) blocks on the amount of opioid pain medications expressed as morphine milliequivalents (MME) used postoperatively in patients who have undergone cesarean delivery (CD) in the setting of complex obstetric surgery (COS).

Primary Endpoint/Outcome: Pain medication requested, expressed as MMEs, from 0-24 and 0-48 hours after surgery.

Secondary Endpoint(s)/Outcome(s):

Total MME at 1-week after surgery Functional assessment of activities of daily life (ADL) at 1-week post operatively Number of unplanned postoperative visits within 6-months of surgery Geographic region of patients needing complex obstetric surgery.

Hypothesis: The investigators hypothesize that utilization of the TAP block will reduce MME requirements by 20% for patients who have undergone CD in the setting of COS.

03

Conditions studied

  • Complex Obstetric Surgery
  • Perioperative Pain Management
  • Cesarean Delivery
  • Postoperative Pain Control

Browse trials for

Keywords

  • Complex obstetric surgery
  • Perioperative pain management
  • cesarean delivery
  • postoperative pain control
04

In context

Pain, Postoperative Reclassified

5,675 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

This study's planned enrollment of 120 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

University of Tennessee is the lead sponsor of 142 studies on the registry; 21 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Compared within Pain, Postoperative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient has a history of a least one of the following:

  • Prior exploratory laparotomy
  • History of non-obstetric open intra-abdominal surgery
  • History of three or more prior cesarean deliveries
  • History of intra-abdominal or pelvic adhesive disease
  • History of abdominal re-exploration surgery

Exclusion criteria

Exclusion Criteria:

  • Planned general anesthesia
  • Supraumbilical skin incision
  • History of less than 3 cesarean deliveries if do not meet other inclusion criteria
  • History of chronic opioid use
  • History of substance abuse (i.e. alcohol, methamphetamine/amphetamine, abuse of prescription opioid medication, or heroin use)
  • History of chronic kidney disease
  • Allergies to bupivacaine or oral analgesics
  • Patient preference
  • Planned cesarean hysterectomy
  • Administration of >4mg morphine to epidural
06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Placebo comparator
    Placebo group

    Placebo group TAP (Transversus Abdominis Plane) block syringe will include 30mL normal saline.

    Drug: Placebo arm

  • Active comparator
    Intervention group

    TAP (Transversus Abdominis Plane) blocks will include 0.5% bupivacaine in 30mL solution of 15mL normal saline and 15mL bupivacaine.

    Drug: Bupivicaine intervention arm

Interventions

  • DrugBupivicaine intervention arm

    TAP blocks in intervention group will include 0.5% bupivacaine in 30mL solution of 15mL normal saline and 15mL bupivacaine

  • DrugPlacebo arm

    Placebo group TAP block syringe will include 30mL normal saline

07

What researchers measure

Primary outcomes

  1. Pain medication requested

    Total pain medication requested expressed in morphine milligram equivalents.

    Time frame: Between 0-24 and 0-48 hours after surgery

Secondary outcomes

  1. Total MME at one week after surgery

    Time frame: One week postoperatively

  2. Functional assessment of activities of daily life (ADL) at one week postoperatively

    Time frame: One week postoperatively

  3. Number of unplanned postoperative visits within six months of surgery

    Time frame: Six months postoperatively

  4. Geographic region of patients needing complex obstetric surgery

    Heat maps to evaluate the distribution of patients across different demographic categories based on race and age within certain zip codes

    Time frame: 24 months - through the duration of the study

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • McDonnell JG, O'Donnell B, Curley G, Heffernan A, Power C, Laffey JG. The analgesic efficacy of transversus abdominis plane block after abdominal surgery: a prospective randomized controlled trial. Anesth Analg. 2007 Jan;104(1):193-7. doi: 10.1213/01.ane.0000250223.49963.0f. PubMed 17179269 ↗
  • Johns N, O'Neill S, Ventham NT, Barron F, Brady RR, Daniel T. Clinical effectiveness of transversus abdominis plane (TAP) block in abdominal surgery: a systematic review and meta-analysis. Colorectal Dis. 2012 Oct;14(10):e635-42. doi: 10.1111/j.1463-1318.2012.03104.x. PubMed 22632762 ↗
  • Zhang, X., et al. (2017).
  • Kehlet, H., et al. (2014).
  • Garmi G, Parasol M, Zafran N, Rudin M, Romano S, Salim R. Efficacy of Single Wound Infiltration With Bupivacaine and Adrenaline During Cesarean Delivery for Reduction of Postoperative Pain: A Randomized Clinical Trial. JAMA Netw Open. 2022 Nov 1;5(11):e2242203. doi: 10.1001/jamanetworkopen.2022.42203. PubMed 36378307 ↗
  • Abdallah FW, Halpern SH, Margarido CB. Transversus abdominis plane block for postoperative analgesia after Caesarean delivery performed under spinal anaesthesia? A systematic review and meta-analysis. Br J Anaesth. 2012 Nov;109(5):679-87. doi: 10.1093/bja/aes279. Epub 2012 Aug 19. PubMed 22907337 ↗
  • Ueshima, H., Higashijima, U., Matsumoto, M., & Imai, S. (2013). The effect of the volume of local anesthetic on the analgesic effect of transversus abdominis plane block in abdominal surgery. Journal of Anesthesia, 27(6), 650-655.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2028, 34 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 34 months is above that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Apr 13, 2025
StartActual
Jul 15, 2025
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion removed; 3 exclusion criteria edited, 1 added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedHistory of abdominoplasty
Exclusion criteria
  • EditedReceivedPlanned general anesthesia
  • AddedSupraumbilical skin incision
  • EditedCesareanPlanned cesarean hysterectomy
  • EditedAdministration of ≥>4mg morphine to epidural
  • RemovedLoss to follow-up
Oct 21, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time framePain medication requestedBetween 24 and 48 hours after surgery → Between 0-24 and 0-48 hours after surgery
Oct 21, 2026
Secondary outcomes
2 removed
What changed in the outcomes
  • RemovedTotal MME requested within first 24 hours postoperativelyTime frame: 24 hours postoperatively
  • RemovedTotal MME requested within 48 hours postoperativelyTime frame: 48 hours postoperatively
Oct 21, 2026
Contact
Study contact's phone or email changed: •••1046→•••1321. See the current contact
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Eligibility 1 inclusion criterion removed; 3 exclusion criteria edited, 1 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedHistory of abdominoplasty
    Exclusion criteria
    • EditedReceivedPlanned general anesthesia
    • AddedSupraumbilical skin incision
    • EditedCesareanPlanned cesarean hysterectomy
    • EditedAdministration of ≥>4mg morphine to epidural
    • RemovedLoss to follow-up
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time framePain medication requestedBetween 24 and 48 hours after surgery → Between 0-24 and 0-48 hours after surgery
    Secondary outcomes 2 removed
    What changed in the outcomes
    • RemovedTotal MME requested within first 24 hours postoperativelyTime frame: 24 hours postoperatively
    • RemovedTotal MME requested within 48 hours postoperativelyTime frame: 48 hours postoperatively
    Contact Study contact's phone or email changed: •••1046→•••1321. See the current contact
    + 3 other changes: verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06925152
Collaborators
Regional One Health
Responsible party
Michael B VanDillen MD (Principal Investigator, University of Tennessee) — Principal investigator
First posted
Apr 13, 2025
Start date
Jul 15, 2025
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Michael VanDillen Fellow physician, PI of study, MD
Contact
mvandill@uthsc.edu
901-646-1321

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion